Another example of a company changing the primaryendpoint during p3 trial: Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study https://investor.lilly.com/news-releases/news-release-details/lilly-announces-change-primary-endpoint-expedition3-study

If phase 3 is positive:how high will it go immediately after the results...?

I hedged my position by buying KTRA.

If it works on GBM,then highly likely on the 15other solid tumor cancers as well. In other words:if P3 results are positive then we have a new breakthrough in cancer treatment. This will not be neglected in the share price. PT $10/share is only for GBM (P/E=7).

I AGREE Flexroy.

They recorded what Les said and played the recorded version including their interference.

Well the show was recorded weeks earlier. So tld could come tomorrow.

tld could come tomorrow.

could be very true. That would give even higher odds tld could be released tomorrow.

"New" Les Goldman video probably recorded 9/8/20...

Someone pointed out Les was wearing the same polo in the video purportedly made on 9/23/20. If you look at the 9/8/20 video, the hosts are wearing the exact same clothing as well. That would be some coincidence if all three were wearing the exact same clothing.... probably recorded the same day

9/8/20 video: https://www.biztvclub.com/tv/search/video/6a63a72571be4a60f2ed7d4b91dcdcd8

"9/23/20" video: https://www.bizvod.com/tv/search/video/a00308b17e89ae098b47db087fb9e4d4";

LG says also:applicable to 15solid cancers.
Indeed 15!!!

tld could come tomorrow when biostatisticians have made their conclusions and report. Thatns why Less says "within weeks" b/c no one really knows: biostatistians work independently.
Anyway I think results will be groundbreaking.

Intraday after halt is announced.Could be today

TLD will be announced intraday,after trading is halted. So her revenge on the shorts will be epical.

0,825 euro = 0,965 dollar

In 2014

Ah ok

Wall Street is closed today

The blinded results presentation of Bosch in 2019 gave us also optimism for non MGMT.

Late breaking and plenary!!!Wow! In the plenary all attendees of SNO will be attending her presentation.

That´s why I bet on GSK: THEY RESTARTED THEIR ONCOLOGY PROGRAMM and like vaccines.

Good analysis. Don´t forget besides UK and FDA approval, also EMA approval in all Europe.

BO + board seat for Linda.

Watch for buyout offer from GSK.

I am not here for $.60 but for >$10/share

Technically very bullish too:52wk high

Jackpot:MC>$300M ==>A-F oncology rule says positiveP3 results=very possible!!!

Interesting analysis from "Tim" on the yahoo board:"Time for a prediction of phase three vaccine results, based on what we know.

Standard of care five year survival in glioblastoma is well established at 5%. This was recently reinforced by James the Cat, who posted 5 year survival comparison of Novocure at 13% vs SOC at 5%. Yup... that came from James Gang. 95% of SOC are dead after 5 years.

We also know the top 100 responding patients in the vaccine trial are cancer free at 5 years or greater. We don’t know who was on what.

Let’s assume 5% of those are SOC. That means the other 95 are vaccine patients. and 95 of 331 total enrolled patients is 29% of all patients earned 5 year survival.

Let’s give SOC some buffer grace. and quadruple the number of 5 year survival on SOC in the top 100 patients from 5% to 20%.

That still leaves 80 patients just in the top 100 reaching 5 years on the vaccine, which would still be 24% of all 331 patients qualifying for a cure of glioblastoma.

IMO, if the vaccine only matched SOC In the 231 patients outside the top 100, both PFS and OS would still be impacted enough from the top 100 to separate from SOC.

To anybody who wants to diss this analysis, please include your own statistical analysis on how far the vaccine would have to fall on its face in the other 231 patients to prevent separation in PFS and OS.

A two month added improvement in survival with the vaccine will match improved survival when chemo was added to SOC 15 years ago.

A three month improvement would ensure FDA approval.

A six month improvement would ensure a new standard of care.

A nine month improvement would shake the oncology medical world.

29% 5 year cancer free survival has never been seen before in any glio trial. Not even close. 29% is more than double what Novocure did.

IMO, the vaccine has to be the reason.

I predict the vaccine does not fall on its face in the other 231 patients. I also predict at least a 6 month extended survival for the vaccine, and a nine month or more extended survival is likely.

Gonna diss me? Bring it. You can’t explain away the longer life of this trial.

Good luck to all longs."

And a board seat for Linda.

5 years at least before results, then another year before commerciamization. By then DCVAX-L has 100% market share in GBM and is owned by Merck.

Be patient...Next time could be Very different.

Btw I love the intraday news from the company.

ESMO is very possible.

Very good news:they´ve been able to collect ALL data and even more data than anticipated. All data from such a long trial and from two continents is very difficult, but they succeeded.
And the deadline for TLD is again confirmed for September

Very good news:they´ve been able to collect ALL data and even more data than anticipated. All data from such a long trial and from two continents is very difficult, but they succeeded.
And the deadline for TLD is again confirmed for September

When? It will happen intraday (and halted) Linda´s revenge on naked shorts.

I see a lot of nervosity.With a little more volume this will go >$1/share before TLD

If they were doing illegal things,Merck would never have sent Duffy to NWBO.

Could there be news today intraday? Very bullish here.

Merck BUYOUT after results $5/share after FDA approval $15/share

Great find!"According to this article in the August 2020 issue of the Mayo Clinic Proceedings: Innovations Quality & Outcomes, “DCVax-L is “the longest acting vaccine in history for GBM” (see pg
13)